Cas:202348-54-7 7-Methylimidazo[1,2-a]pyridine-2-carbaldehyde manufacturer & supplier

Chemical Name:7-Methylimidazo[1,2-a]pyridine-2-carbaldehyde

CAS.NO:202348-54-7

Synonyms:Imidazo[1,2-a]pyridine-2-carboxaldehyde, 7-methyl-;7-Methylimidazo[1,2-a]pyridine-2-carbaldehyde;Imidazo[1,2-a]pyridine-2-carboxaldehyde, 7-methyl-(9Cl)

Molecular Formula:C₉H₈N₂O

Molecular Weight:160.173

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:1.2±0.1 g/cm3

Index of Refraction:1.622

PSA:34.37000

Exact Mass:160.063660

LogP:1.87

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Imidazo[1,2-a]pyridine-2-carboxaldehyde, 7-methyl- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Imidazo[1,2-a]pyridine-2-carboxaldehyde, 7-methyl-(9Cl) physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Imidazo[1,2-a]pyridine-2-carboxaldehyde, 7-methyl- Use and application,Imidazo[1,2-a]pyridine-2-carboxaldehyde, 7-methyl- technical grade,usp/ep/jp grade.

Related News: The expansion will include six 1,000L small molecule reactors, four 1,500L vessels, and isolation equipment providing mid-scale capacity to bridge between early-phase and late-phase production. ethyl [2-[(8S,9R,10S,11S,13S,14S,16S,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] carbonate manufacturers The development of various enabling technologies has been critical in expanding the potential of biocatalytic processing, as well as in promoting its uptake across the pharmaceutical industry. 4,6,4′,6′-tetranitro-2,2′-methanediyl-di-phenol suppliers Zynteglo is a one-time treatment for a blood disorder known as beta thalassaemia in patients 12 years and older who require regular blood transfusions. N-propyl-1-[3-(trifluoromethyl)phenyl]propan-2-amine vendor & factory The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered.,“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.”